SCA Personal Care to increase advertising support for its bladder-control products
PHILADELPHIA SCA Personal Care North America on Tuesday announced that it will be increasing its advertising support behind its Tena bladder-control products in 2009.
“More than 25 million men and women in the United States currently suffer from bladder control issues,” stated Bruno Zepeda, president of SCA Personal Care in North America.
The Tena brand, formerly known as Serenity in the U.S., will begin offering its first gender-specific protective underwear line this month, the supplies stated, which will be coupled with an aggressive education campaign to increase awareness of and understanding about bladder control.
“Our internal research shows that the majority of men who suffer from bladder control issues don’t use products designed specifically for them, and that 60% of them do not use any protection at all,” stated Spencer Deane, VP marketing for SCA Personal Care in North America. “Our new Tena Men products are designed specifically for the male anatomy to provide comfortable and discreet protection where men need it most.”
The education campaign kicks off this month with an alliance with two leading men’s health organizations — Men’s Health Network and Us TOO International — to bring bladder control information, advice and solutions to men coping with this condition.
The campaign will begin with the launch of an educational web site about male bladder control, where men can go for information and advice.
“Not surprisingly, research indicates that the Internet is a man’s No. 1 source for information about sensitive health topics such as bladder control issues,” Deane said.
SC Personal Care launched its Core Wellness program for women in January. Core Wellness is a free pelvic health initiative with international pelvic fitness expert Kari Bo. Women with a given a free DVD of exercises that help strengthen pelvic floor muscles —the group of muscles located on the underside of the pelvis responsible for bladder control — thereby improving or curing symptoms of bladder weakness.
New supplement designed for weight-loss surgery patients
ST. LOUIS Undergoing weight-loss surgery means making sacrifices, particularly in the area of food, but this can sometimes place patients at risk for vitamin and mineral deficiencies. A company in St. Louis, however, has created a prescription nutritional supplement for patients who have undergone the surgery.
ProBarimin QT, made by Fleming Pharmaceuticals, is a fruit-flavored supplement that dissolves in the mouth.
“Although there are over-the-counter supplements for WLS patients, ProBarimin QT is specially formulated to meet the unique nutritional and intake requirements of WLS patients,” Fleming president Phill Dritsas said.
The supplement includes vitamins such as B12, C and D and minerals such as iron, selenium and zinc.
The patent for the supplement is pending.
New lab test determines if aspirin is effective for heart attack, stroke prevention
DENVER Corgenix Medical on Tuesday introduced a laboratory test in the Wichita, Kan., area that determines if the aspirin being taken to prevent a heart attack or stroke is effective.
The AspirinWorks Test is available to doctors across Kansas through AMS Laboratory. Edwin Harned, AMS Laboratory president and CEO, said he’s excited to field a test that gives physicians a tool to identify patients who are not benefiting from their aspirin therapy.
“Any time we have the chance to offer a test that gives the physician and patient good information about the validity of a drug that they are taking, we think it’s a great test,” Harned said.
The AspirinWorks Test determines the effect of aspirin on platelets by measuring the level of the biomarker called thromboxane B2. The higher the levels of thromboxane B2, the stickier the blood platelets, and the less impact the aspirin is having. This information allows physicians to individualize a patient’s therapy, which may be as simple as adjusting the dose.
“Not everyone responds the same to the same dose of aspirin,” noted Gordon Ens, clinical affairs director for Corgenix Medical. “So we came up with a simple, non-invasive test to measure aspirin effect in individuals taking aspirin to reduce the risk of a heart attack and stroke.”
AspirinWorks is the only FDA-cleared test that measures urinary thromboxane B2 to accurately determine aspirin effect in apparently healthy individuals. Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained at the doctor’s office or AMS Laboratory patient service centers.
The AspirinWorks Test is reimbursed by most insurance carriers, and covered under Medicare and Medicaid, the company stated.